Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

In its upcoming report, Gilead Sciences (GILD) is predicted by Wall Street analysts to post quarterly earnings of $1.83 per share, reflecting a decline of 3.7% compared to the same period last year. Revenues are forecasted to be $7.57 billion, representing a year-over-year increase of 0.1%.The current level reflects an upward revision of 2.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Gilead metrics that are routinely monitored and predicted by Wall Street analysts.Analysts predict that the 'Total product sales- Total' will reach $7.53 billion. The estimate suggests a change of -0.2% year over year.Analysts forecast 'Revenues- Royalty contract and other revenues' to reach $38.66 million. The estimate indicates a change of +17.2% from the prior-year quarter.Analysts expect 'Product Sales- Liver Disease- Vemlidy- Total' to come in at $258.86 million. The estimate suggests a change of -0.4% year over year.The consensus estimate for 'Product Sales- Oncology- Cell Therapy- Yescarta- Total' stands at $324.13 million. The estimate indicates a change of -16.9% from the prior-year quarter.The combined assessment of analysts suggests that 'Product Sales- HIV- Biktarvy- U.S.' will likely reach $3.10 billion. The estimate indicates a change of -0.8% from the prior-year quarter.According to the collective judgment of analysts, 'Product Sales- HIV- Symtuza-Revenue share- U.S.' should come in at $102.10 million. The estimate suggests a change of -8.8% year over year.The consensus among analysts is that 'Product Sales- Oncology- Cell Therapy- Yescarta- U.S.' will reach $117.01 million. The estimate indicates a change of -27.3% from the prior-year quarter.Analysts' assessment points toward 'Product Sales- HIV- Odefsey- U.S.' reaching $225.96 million. The estimate indicates a change of -10.3% from the prior-year quarter.It is projected by analysts that the 'Product Sales- Total HIV- U.S.' will reach $4.63 billion. The estimate suggests a change of +2.1% year over year.The average prediction of analysts places 'Product Sales- Other- Other- U.S.' at $40.32 million. The estimate suggests a change of -20.9% year over year.The collective assessment of analysts points to an estimated 'Product Sales- Oncology- Cell Therapy- Tecartus- U.S.' of $38.05 million. The estimate indicates a year-over-year change of -28.2%.Based on the collective assessment of analysts, 'Product Sales- Liver Disease- Other Liver Disease- U.S.' should arrive at $141.36 million. The estimate points to a change of +143.7% from the year-ago quarter. View all Key Company Metrics for Gilead here>>> Shares of Gilead have demonstrated returns of +17.6% over the past month compared to the Zacks S&P 500 composite's +0.5% change. With a Zacks Rank #3 (Hold), GILD is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks